{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:00:15Z","timestamp":1789585215086,"version":"build-2803163510"},"reference-count":16,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>We characterized linear growth in infants and children with X-linked hypophosphatemia (XLH).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Provide linear growth curves for children with XLH from birth to early adolescence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Data from 4 prior studies of XLH were pooled to construct growth curves. UX023-CL002 was an observational, retrospective chart review. Pretreatment data were collected from 3 interventional trials: two phase 2 trials (UX023-CL201, UX023-CL205) and a phase 3 trial (UX023-CL301).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Medical centers with expertise in treating XLH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Children with XLH, 1-14 years of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>None.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Height-for-age linear growth curves, including values for the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles for children with XLH compared to population norms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 228 patients (132 girls, 96 boys) with 2381 height measurements were included. Nearly all subjects (&amp;gt; 99%) reported prior management with supplementation therapy. Compared to the Center for Disease Control and Prevention growth curves, boys at age 3 months, 6 months, 9 months, 1 year, and 2 years had median height percentiles of 46%, 37%, 26%, 18%, and 5%, respectively; for girls the median height percentiles were 52%, 37%, 25%, 18%, and 7%, respectively. Annual growth in children with XLH fell below that of healthy children near 1 year of age and progressively declined during early childhood, with all median height percentiles &amp;lt; 8% between 2 and 12 years old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Children with XLH show decreased height gain by 1 year of age and remain below population norms thereafter. These data will help evaluate therapeutic interventions on linear growth for pediatric XLH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa495","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T12:36:59Z","timestamp":1595939819000},"page":"3243-3249","source":"Crossref","is-referenced-by-count":44,"title":["Growth Curves for Children with X-linked Hypophosphatemia"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-5359","authenticated-orcid":false,"given":"Meng","family":"Mao","sequence":"first","affiliation":[{"name":"UBiometrics, Ultragenyx Pharmaceutical Inc., Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-6768","authenticated-orcid":false,"given":"Thomas O","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Whyte","sequence":"additional","affiliation":[{"name":"Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri"},{"name":"Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children - St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Skrinar","sequence":"additional","affiliation":[{"name":"Clinical Outcomes, Research and Evaluation, Ultragenyx Pharmaceutical Inc., Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yin","family":"Chen","sequence":"additional","affiliation":[{"name":"UBiometrics, Ultragenyx Pharmaceutical Inc., Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"San Martin","sequence":"additional","affiliation":[{"name":"Clinical Development, Ultragenyx Pharmaceutical Inc., Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Rogol","sequence":"additional","affiliation":[{"name":"Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"issue":"7","key":"2021122105540028100_CIT0001","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2021122105540028100_CIT0002","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect."},{"issue":"Suppl 1","key":"2021122105540028100_CIT0003","first-page":"119","article-title":"Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets","volume":"15","author":"Cagnoli","year":"2017","journal-title":"Pediatr Endocrinol Rev."},{"issue":"8","key":"2021122105540028100_CIT0004","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"18","key":"2021122105540028100_CIT0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","journal-title":"N Engl J Med."},{"issue":"2","key":"2021122105540028100_CIT0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1067\/mpd.2001.108955","article-title":"Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets","volume":"138","author":"Baroncelli","year":"2001","journal-title":"J Pediatr."},{"issue":"6","key":"2021122105540028100_CIT0007","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","article-title":"Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets","volume":"113","author":"Haffner","year":"2004","journal-title":"Pediatrics."},{"key":"2021122105540028100_CIT0008","article-title":"Burosumab: first global approval","author":"Lamb","year":"2018","journal-title":"Drugs."},{"issue":"3","key":"2021122105540028100_CIT0009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10189","key":"2021122105540028100_CIT0010","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"issue":"21","key":"2021122105540028100_CIT0011","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"key":"2021122105540028100_CIT0012","author":"Kuczmarski"},{"key":"2021122105540028100_CIT0013","article-title":"Supplemental material for \u201cGrowth Curves for Children with X-linked Hypophosphatemia,","author":"Mao","year":"2020"},{"issue":"5 Suppl","key":"2021122105540028100_CIT0014","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jpeds.2014.02.027","article-title":"Etiologies and early diagnosis of short stature and growth failure in children and adolescents","volume":"164","author":"Rogol","year":"2014","journal-title":"J Pediatr."},{"issue":"3","key":"2021122105540028100_CIT0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0022-3476(85)80501-1","article-title":"Clinical longitudinal standards for height and height velocity for North American children","volume":"107","author":"Tanner","year":"1985","journal-title":"J Pediatr."},{"issue":"6","key":"2021122105540028100_CIT0016","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1210\/jc.2013-4455","article-title":"Age-based reference ranges for annual height velocity in US children","volume":"99","author":"Kelly","year":"2014","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa495\/33565427\/dgaa495.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/3243\/41828433\/dgaa495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/3243\/41828433\/dgaa495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T05:55:56Z","timestamp":1640066156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/10\/3243\/5877298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,28]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa495","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,28]]}}}